(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of 19.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.87%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Arvinas's revenue in 2025 is $263,400,000.On average, 9 Wall Street analysts forecast ARVN's revenue for 2025 to be $16,128,034,390, with the lowest ARVN revenue forecast at $9,284,202,045, and the highest ARVN revenue forecast at $25,651,906,391. On average, 8 Wall Street analysts forecast ARVN's revenue for 2026 to be $19,388,164,745, with the lowest ARVN revenue forecast at $14,882,232,019, and the highest ARVN revenue forecast at $27,034,220,918.
In 2027, ARVN is forecast to generate $33,007,263,882 in revenue, with the lowest revenue forecast at $20,287,700,765 and the highest revenue forecast at $58,758,683,165.